329911-79-7

Upstream product

• 84796-63-4 β-phenylalanine 
• 801317-50-0 4-oxo-4-(4-Boc-piperazin-1-yl)butyrylglycine 
• 3646-50-2 3-Amino-3-phenylpropionic acid 
• 801317-52-2 4-oxo-4-(4-Boc-piperazin-1-yl)butyrylglycine succinimide ether 
• 801317-51-1 4-oxo-4-(4-Boc-piperazin-1-yl)butyrylglycine pentafluorophenyl ether 
• 329911-77-5 methyl tert-butoxycarbonyl-glycyl-D,L-β-phenyl-β-alaninate 
• 22838-46-6 methyl 3-amino-3-phenylpropionate hydrochloride 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 801317-49-7 4-oxo-4-(4-Boc-piperazin-1-yl)butyric acid succinimide ether 
• 329911-76-4 pentafluorophenyl 4-(4-tert-butoxycarbonyl-piperazin-1-yl)-4-oxobutanoate 
• 288851-44-5 4-(4-tert-butoxycarbonyl-piperazin-1-yl)-4-oxobutanoic acid 
• 329911-78-6 methyl (4-[4-tert-butoxycarbonyl-piperazin-1-yl)-4-oxobutyryl]glycyl-D,L-β-phenyl-β-alaninate 

Relevant academic research and scientific papers

Synthesis and antiaggregatory activity of RGD-peptidomimetics based on 4-oxo-4-(piperazine-1-yl)butyric acid as Arg-mimetic

A scheme of synthesis of previously obtained RGDF-peptidomimetic-4-oxo- 4-(piperazine-1-yl)butyrylglycyl-D,L-β-phenyl-β-alanine (I), was simplified. The novel RGDF-peptidomimetic - 4-o-xo-4-(piperazine-1-yl) butyryl-glycyl-L-aspartyl-L-phenylalanine (II was synthesized with the use of 4-oxo-4-(piperazine-1-yl)butyric acid as arginyl mimetic. The obtained pseudopeptides were able to inhibit both platelet aggregation in human blood and binding of fibrinogen to its receptor.

Synthesis and properties of peptidomimetics - Inhibitors of platelet aggregation

The literature data on effective approaches to the development of the novel peptidomimetics, antagonists of fibrinogen GP IIb/IIIa receptors as potential antithrombotic agents are generalized and systematized in the review. The data obtained by the authors on the synthesis and properties of novel peptidomimetics are reported.

Synthesis and antiaggregation activity of a new RGDF peptidomimetic

A new RGDF peptidomimetic, [4-oxo-4-(pyperazin-1-yl)butyryl]glycyl-D,L-β-phenyl-β-alanine was synthesized. The arginyl mimetic used was the 4-oxo-4-(piperazin-1-yl)butanoic acid residue, and the Asp-Phe chain is replaced by a β-phenyl-β-alanine residue. The synthesized pseudopeptide showed ability to inhibite ADF-induced thrombocyte aggregation in a thrombocyte-rich rat blood plasma (IC50 8.7 × 10-9 M).